

Remarks

Claims 1-12 and 14-17 are pending in this application. Claim 13 has been canceled previously. Claims 1, 2, and 7-10 have been amended.


In reviewing the previous amendment in preparation for paying the issue fee, the undersigned noticed that certain corrections were needed, and certain clarifications were desirable. The present amendment is the result.

The necessary corrections were the addition of a period to end claim 7, and the addition of the language "A compound" at the beginning of claim 8. In claims 9 and 10, the [A] and [B] have been replaced by (A) and (B) respectively, to eliminate the possibility of confusion as to whether the A and B were to be deleted or not. The remaining revisions are for clarification of language and punctuation and are self-explanatory.

It is requested that this amendment be entered, and that the amended application proceed to issuance.

Respectfully submitted,

Reg. No.: 31018
Phone: (203) 812-2712
Date: 3/7/05



William F. Gray
Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516-4175